YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
(RTTNews) - Gyre Therapeutics, Inc. (GYRE), a commercial-stage biopharmaceutical company, announced financial results for the second quarter of 2026, reflecting a wider net loss and a slip in revenue. The company affirmed its full-year 202…
Q2 2026 revenue of $29.1 million; GAAP basic EPS: $(0.12) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed NDA for F351 (hydronidone) for CHB-induced liver fibrosis accepted by China’s CDE in May 2026 SAN DIEGO, Aug. 07…
Cytokinetics (CYTK) came out with a quarterly loss of $1.5 per share versus the Zacks Consensus Estimate of a loss of $1.63. This compares to a loss of $1.12 per share a year ago. These figures are adjusted for non-recurring items. This qu…
SAN DIEGO, July 16, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or the “Company”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United States and China, t…
Over the last 7 days, the United States market has risen 1.3% and over the past 12 months, it is up by an impressive 28%, with earnings forecasted to grow by 17% annually. In this robust environment, identifying high growth tech stocks inv…
Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: Gyre Therapeutics, Inc. GYRE is a biotechnology company which is focused on organ fibrosis and inflammatory diseases. The Zacks Consensus Estimate for its current y…
Gyre Therapeutics, Inc. (GYRE) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to break-even earnings per share a year ago. These figures are adjusted for non-recurrin…
The United States market remained flat over the last week, yet it has experienced a 30% rise over the past 12 months with earnings forecasted to grow by 16% annually. In this context of robust growth potential, identifying high-growth tech…
Over the last 7 days, the United States market has experienced a 1.6% drop, yet it has seen a significant 15% rise over the past year, with earnings expected to grow by 16% annually. In this context of fluctuating market conditions and pro…
Full-year 2025 revenue increased 10% year-over-year to $116.6 million, within revised guidance range Full year 2026 revenue guidance of $100.5 to $111.0 million Entered into agreement to acquire Cullgen to gain targeted protein degradation…
Gyre Therapeutics (GYRE) announced its agreement to acquire Cullgen, a privately-held, clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degrader and degrader antibody conjugate therapies…
Health care stocks declined late Monday afternoon with the NYSE Health Care Index falling 1.2% and t PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
As February 2026 begins, the U.S. stock market is experiencing a strong start with major indices like the Dow Jones Industrial Average and S&P 500 showing significant gains, driven by positive economic indicators such as improved factory a…
As the U.S. stock market navigates a week marked by tech earnings and geopolitical tensions, major indices like the Dow Jones, S&P 500, and Nasdaq have shown modest gains despite recent declines. Amidst this backdrop of fluctuating market…
As the U.S. market continues to reach new highs, with the S&P 500 and Dow Jones Industrial Average setting records despite concerns over a DOJ probe into Fed Chair Powell, investors are keeping a keen eye on high-growth tech stocks that co…
As the U.S. stock market continues to reach new heights, with the S&P 500 setting all-time records and major indices logging consecutive gains, investors are keenly observing the dynamics that drive these trends. In this buoyant environmen…
The U.S. stock market recently experienced a significant downturn, with major indices such as the Nasdaq and S&P 500 closing sharply lower, driven by a notable decline in technology shares. In this environment of heightened volatility and…
Net income of $5.9 million and $11.2 million for the three and nine months ended September 30, 2025, respectively Full-year revenue guidance revised to $115-118 million (from $118 - $128 million previously) due to delayed Etorel® (Nintedan…
Guardant Health (GH) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to a loss of $0.45 per share a year ago. These figures are adjusted for non-recurring items. This…
Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: Gyre Therapeutics, Inc. GYRE is a biotechnology company which is focused on organ fibrosis and inflammatory diseases. The Zacks Consensus Estimate for its current y…
SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, toda…
As of October 2025, the U.S. stock market has been experiencing significant volatility, with major indices like the Nasdaq and S&P 500 rebounding sharply after recent declines due to geopolitical tensions. This dynamic environment undersco…
SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic dise…
Septerna, Inc. (SEPN) shares soared 7% in the last trading session to close at $22.49. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 38% gain over the past fo…
As the U.S. market faces potential volatility with major stock indexes experiencing slight fluctuations ahead of a government shutdown deadline, investors are keenly observing economic indicators that could impact small-cap stocks. In such…
SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic dis…
Investing.com - Jefferies initiated coverage on Crescent Biopharma Inc (NASDAQ:CBIO) with a Buy rating and set a price target of $26.00. The stock, currently trading at $15.06, has shown strong momentum with a 9.21% return over the past we…
SAN DIEGO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic dise…
As the S&P 500 and Nasdaq reach record highs, driven by optimistic expectations of Federal Reserve rate cuts following a steady inflation report, investors are increasingly looking towards small-cap stocks for potential growth opportunitie…
Net income of $1.6 million and $5.3 million for the three and six months ended June 30, 2025, respectively; reaffirms full-year revenue guidance of $118-128 million Ping Zhang, Executive Chairman, appointed interim CEO as Dr. Han Ying tran…
Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $1.03. This compares to a loss of $0.51 per share a year ago. These figures are adjusted for non-recurring items. This…
SAN DIEGO, June 10, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic dise…
Gyre Therapeutics, Inc. (NASDAQ:GYRE), a biopharmaceutical company developing innovative fibrosis-focused therapies, has successfully closed a public offering, raising approximately $23 million in gross proceeds. The offering included 2,55…
SAN DIEGO, May 29, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disea…
SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced the pricing of its previously announced underwritten pu…
SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced that it has commenced an underwritten public offering o…